ECSCR functions as a potential tumor suppressor in breast cancer cells Authors: Sen Lian, Yi Huang, Ling Liang, Yiping Yang, Yingxi Mo, Shan Wang, Changyuan Wei Published: 2025 ABSTRACT AbstractBreast cancer is the most commonly diagnosed malignancy among women worldwide. Triple-negative breast cancer (TNBC), a particularly aggressive subtype, is unresponsive to endocrine and targeted therapies. It is characterized by high rates of invasion and recurrence, a poor prognosis, and limited treatment options. Resveratrol, a natural polyphenolic compound, possesses well-documented anticancer properties. Given the differential sensitivity of the MDA-MB-231 (TNBC) and MCF-7 (luminal) cell lines to resveratrol, we treated these cells with resveratrol and performed RNA sequencing followed by RT-qPCR validation. Our analysis revealed significantly elevated expression of ECSCR (Endothelial Cell Surface Expressed Chemotaxis and Apoptosis Regulator) in resveratrol-treated MDA-MB-231 cells compared to controls, whereas no significant change was observed in MCF-7 cells. Although the role of ECSCR in breast cancer remains poorly characterized, we investigated its functional significance by establishing lentiviral-mediated ECSCR overexpression in breast cancer cells. In vitro, ECSCR overexpression suppressed cellular proliferation and migration while promoting apoptosis. Consistently, in vivo experiments demonstrated a reduced tumorigenic capacity of ECSCR-overexpressing cells. Collectively, our findings indicate that ECSCR exerts tumor-suppressive effects by inhibiting proliferation and migration, inducing apoptosis, and suppressing tumorigenesis. Notably, the growth-inhibitory effects of resveratrol on TNBC may be mediated through the upregulation of ECSCR. These results identify ECSCR as a promising therapeutic target for breast cancer intervention strategies.Supplementary InformationThe online version contains supplementary material available at 10.1007/s12032-025-03228-9.Keywords: Breast cancer, TNBC, ECSCR, Proliferation, Apoptosis Introduction Breast cancer is the leading cause of cancer-related mortality in women and, as of 2020, the most commonly diagnosed cancer worldwide [1]. The disease is classified into four principal molecular subtypes according to the expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2): luminal A, luminal B, HER2-positive, and triple-negative breast cancer (TNBC) [2, 3]. TNBC, which lacks expression of ER, PR, and HER2, is unresponsive to endocrine and targeted therapies. It is also characterized by high invasiveness, frequent recurrence, and a poor prognosis [4–6]. Therefore, identifying more sensitive biomarkers and developing novel therapeutic targets are urgently needed to improve outcomes in TNBC. RNA sequencing (RNA-seq) was performed on MDA-MB-231 cells treated with resveratrol (RES), and differentially expressed genes were analyzed. Real-time quantitative PCR (RT-qPCR) was then used to validate gene expression changes in both MCF-7 and MDA-MB-231 cells following RES treatment. Notably, ECSCR (endothelial cell surface expressed chemotaxis and apoptosis regulator) was significantly upregulated in RES-treated MDA-MB-231 cells, while no significant change was observed in MCF-7 cells. Previous studies indicate that ECSCR regulates neovascularization, and its inhibition has been reported to enhance insulin sensitivity in murine models [7, 8]. Interestingly, overexpression of ECSCR in stromal tissues of non-small cell lung cancer (NSCLC) is associated with improved overall survival in early-stage patients [9]. Conversely, studies in bovine mastitis have implicated ECSCR downregulation in apoptosis, inflammation, and disease progression [10]. Resveratrol (RES), a phytoalexin produced by plants under stress conditions [11], exhibits antioxidant, anti-inflammatory, and direct anti-tumor properties [12–14]. It inhibits the growth of various cancer cell types by modulating pathways such as apoptosis and autophagy. Although some studies report RES-mediated inhibition of TNBC [15–17], discrepancies exist regarding its half-maximal inhibitory concentration (IC₅₀) values for MDA-MB-231 and MCF-7 cells across different experiments, including our own [18, 19]. Despite these findings, the role of ECSCR in breast cancer remains poorly understood. This study therefore aims to elucidate the functional significance of ECSCR in breast cancer pathogenesis and therapy (Fig. 1). Schematic workflow of the study investigating ECSCR in breast cancer cells Materials and methods Cell lines and culture MCF-7, MDA-MB-231, BT-474, and 4T1 were purchased from the Shanghai Cell Bank of the Shanghai Academy of Sciences. All cell lines were cultured in DMEM or RPMI-1640 media (ThermoFisher) supplemented with 10% FBS (Sigma-Aldrich) and 1% Penicillin-Streptomycin (ThermoFisher). All cells were cultivated in a humidified incubator at 37℃ supplemented with 5% CO2. Measurement of cell proliferation Cell viability was determined using the CCK-8 Cell Counting Kit (Vazyme). Briefly, 10 µl of CCK-8 was added to each well of a 96-well plate, followed by incubation for 2 h in the absence of light, and finally, the absorbance at 450 mm wavelength was detected by an enzyme marker. The concentrations of resveratrol and other agents used in functional assays were chosen based on our determined IC₅₀ values for each cell line. Colony formation experiments An appropriate amount of cell suspension was added to each well of a 6-well plate, and the medium was changed every 7 days, removed after 12 to 14 days, and the staining was fixed by adding 0.1% (w/v) crystalline violet containing 4% paraformaldehyde for 30 min. After washing and drying, photographs were taken and recorded using an inverted microscope (Carl Zeiss). Transwell migration assay Twenty-four-well 8-µm pore size transwell chambers (Corning) were used. Serum-free medium was added to the upper chamber to resuspend the cells, and a complete medium was added to the lower chamber. After 48 h, the medium was removed and the top of the Transwell membrane was cleaned with a cotton swab to remove cells that had not passed through the membrane. Cells on the bottom of the membrane were fixed and stained with 0.1% (w/v) crystal violet containing 4% paraformaldehyde for 20 min. After washing and drying, photographs were taken and recorded using an inverted microscope (Carl Zeiss). Western blotting The appropriate volume of cell lysate RIPA was added to the collected cell precipitate, and the supernatant was centrifuged in an ice bath after 30 min. Protein concentration was measured and normalized using the BCA Protein Assay Kit (Thermo Scientific), and protein was denatured by adding a loading buffer containing 5% β-mercaptoethanol and heating at 100 degrees Celsius for 5 min. Protein samples (15 µg) were subjected to 4%−20% SDS-PAGE electrophoresis and transferred to a nitrocellulose membrane (Pall). The nitrocellulose membranes were blocked with 5% skim milk and then incubated overnight at 4 °C with the addition of the appropriate primary antibody, after which the membranes were washed and incubated with the appropriate secondary antibody. The final washed membrane was scanned using the Odyssey CLx Imaging System (LI-COR Biosciences). Flow cytometry The prepared cells were processed according to the instructions of the Annexin V-FITC/PI Apoptosis Detection Kit (Vazyme) or the Annexin V-APC/PI Apoptosis Detection Kit (Vazyme) and finally detected using the CytoFlex flow cytometer (BECKMAN). RNA extraction and RT-qPCR Total RNA was extracted and purified by using AxyPrep Multisource Total RNA Miniprep Kit (Axygen). The cDNA was reverse transcribed from 1 µg of total RNA using HiScript III RT SuperMix for qPCR (+ gDNA wiper) (Vazyme). PCR reactions were prepared by using ChamQ Universal SYBR qPCR Master Mix (Vazyme) followed by the real-time PCR using Applied Biosystems 7500 Real-Time PCR System (Applied Biosystems). The nucleotide sequence of each primer is shown in Table 1. Target gene mRNA expression level is relative to GAPDH expression. Table 1Primer sequences for RT-qPCRGene nameForward(F)/Reverse(R)Sequence (5’ to 3’)TIE1FGAGACGCACCTTCACCTACCRCTCCGACCAGCACATTCCSERPINF1FCGGACCCTAAGGCTGTTTRCCATCCTCGTTCCACTCATHBS4FTGTCAGCAACCCTAACCARCACAGATGTCTCCCACTCCECSCRFTCCTGGGCTTCCTCCTGTRCTGCTTGTGCCTCCGTCTC3AR1FAGGTTTCCAGGATTATTACARAAAGCAACTATTGGCAGACGB5/8FGACCCCACCATAGGCAGAGRGGTAGTTGCACACCACCTGASPXFGCAACAACCTTGGCTCTTTRTTTGGGCTTCGTCTTTCCCALCBFGCTCTCAGTATCTTGGTCCTGRCACATAGTCCTGCACCAGTGIL4RFGCGAGTGGAAGATGAATGGTCRCAGGTCAGCAGCAGAGTGTNPR2FTCATCGCTGGCTGCTTCTATRCTCTCGGTCATTGTTCTTGTCCGAPDHFCGACCACTTTGTCAAGCTCARAGGGGAGATTCAGTGTGGTG Primer sequences for RT-qPCR RNA sequencing RNA Extraction and Purification Total RNA was extracted using the MJzol Animal RNA Extraction Kit (MagBeads) according to the manufacturer’s instructions and checked using an Agilent 4200 TapeStation (Agilent Technologies). RIN numbers were used to determine RNA integrity. Eligible total RNA was further purified using the RNAClean XP Kit (Beckman Coulter) and RNase-Free DNase Set (QIAGEN). Purified total RNA was subjected to mRNA isolation, fragmentation, first-strand cDNA synthesis, second-strand cDNA synthesis, end repair, 3’-end plus A, ligation of junctions, and enrichment according to the experimental instructions to complete the library construction of sequencing samples. An Illumina NovaSeq6000 sequencer was used, and the sequencing mode was PE150. Analysis of online databases The mRNA sequencing data of ECSCR in breast cancer tumor tissues and paracancerous tissues were downloaded from the TCGA database (https://www.acbi.com/static/index.html#/pan_cancer) and subjected to statistical analysis. In the online tool Kaplan-Meier Plotter (https://kmplot.com/analysis/index.php?p=service.), the search term “breast cancer” was entered, and the ECSCR probe “227780_s_at” was selected. The effect of high and low ECSCR expression on the prognosis of breast cancer patients was then analyzed, and the results were downloaded. Construction of ECSCR overexpressed cell lines Cells overexpressing ECSCR (ECSCR-OE) and cells not overexpressing ECSCR (ECSCR-NC) were constructed by lentiviral transfection, then the successfully transfected cells were screened with puromycin, and the overexpression of the cells was verified by RT-qPCR and WB assay. The overexpressed sequence corresponds to the CDS region of ECSCR (https://www.ncbi.nlm.nih.gov/nuccore/BC146913). Animal studies BALB/c nude female mice (weight 11–14 g, 4 weeks old) were obtained from the Animal Experiment Center of Guangxi Medical University. All animal studies were approved by the Animal Ethics Approval Committee of Guangxi Medical University. Cell lines with or without ECSCR overexpression in the logarithmic growth-phase were resuspended into a concentration of 1 × 107 per mL, and 100 µL were inoculated subcutaneously into the right lateral abdomen of the nude mice. Tumor size and body weight were measured every other day. The experiment was terminated at approximately 4 weeks post-tumor inoculation. Tumor volume was estimated using the equation: Volume = (Length × Width2)/2. Statistical analysis All data are presented as mean ± standard deviation, and statistical significance was assessed using a two-tailed Student’s t-test or rank sum test. *P < 0.05 was considered statistically significant. Results RES inhibits the proliferation of breast cancer cell lines with different concentrations Previous studies have shown that RES can inhibit the proliferation of cancer cells. We measured the IC50 of RES on different breast cancer cell lines. The IC50 values of RES for MCF-7, MDA-MB-231, BT-474, and 4T1 were 80.08 µM, 20.33 µM, 150.7 µM, and 8.221 µM, respectively (Table 2). The results showed that the IC50 of MDA-MB-231, a TNBC cell line, was lower than that of MCF-7. This suggested that MDA-MB-231 is more sensitive to RES than MCF-7 (Fig. 2). In other words, TNBC is more sensitive to RES than non-TNBC. Table 2IC50 values of Resveratrol in different breast cancer cell linesCell linesRES IC50 (µM)MCF-780.08MDA-MB-23120.33BT-474150.74T18.221 IC50 values of Resveratrol in different breast cancer cell lines RES inhibits the proliferation of breast cancer cell lines with different concentrations. IC₅₀ values of resveratrol in different breast cancer cell lines were determined using CCK8 RNA sequencing of MDA-MB-231 with or without RES, bioinformatics-based analysis was performed on the RNA-seq data To find out the potential mechanism of drug sensitivity difference, MDA-MB-231 cells were subjected to RNA sequencing (RNA-seq) after treating with DMSO as a control group or RES for the experimental group. The possible functions of differentially expressed genes were analyzed using Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and Gene set enrichment analysis (GSEA). (Fig. 3). Bioinformatics-based analysis was performed on the RNA-seq data. (a) Volcano plot of the differentially expressed genes. A total of 49 genes were identified as significantly upregulated or downregulated (|log₂FC| ≥ 1 and P < 0.05). (b) Heatmap of the differentially expressed genes. The top 49 up-regulated and the top 51 down-regulated genes are shown. (c) GO enrichment analysis of the differentially expressed genes. (b) KEGG enrichment analysis of the significantly differentially expressed genes. (d) GSEA of the differentially expressed genes GO enrichment analysis revealed that resveratrol treatment significantly altered biological processes related to immune regulation (e.g., negative regulation of adaptive immune response, T cell differentiation), angiogenesis (e.g., negative regulation of angiogenesis), and cellular metabolism (e.g., vitamin metabolic process, response to xenobiotic stimulus). Molecular functions such as cytokine receptor activity were also enriched, suggesting a multi-faceted impact on MDA-MB-231 cells. KEGG pathway analysis further identified specific signaling pathways influenced by resveratrol. These included immune and inflammatory pathways (e.g., Systemic lupus erythematosus, Neutrophil extracellular trap formation), cell death regulation (Necroptosis), hormone metabolism (Ovarian steroidogenesis, Steroid hormone biosynthesis), and xenobiotic metabolism (Metabolism of xenobiotics by cytochrome P450). The enrichment of ATP-dependent chromatin remodeling indicated potential epigenetic effects. GSEA analysis broadly supported the KEGG findings, showing significant enrichment of gene sets involved in Neutrophil extracellular trap formation, Systemic lupus erythematosus, and Ovarian steroidogenesis. Additional enriched sets related to metabolism (e.g., Fructose and mannose metabolism, Retinol metabolism) and other physiological processes were identified, confirming a system-wide transcriptional response. RT-qPCR validation of differentially expressed genes and online database analysis of ECSCR We then used RT-qPCR to verify that the expression levels of these differentially expressed genes matched the RNA sequencing results. Results showed that ECSCR was significantly up-regulated in MDA-MB-231 after treatment with RES while there was no significant change in MCF-7 under the same conditions (Fig. 4a). ECSCR expression was higher in normal breast tissues than in tumor tissues, as demonstrated in the TCGA database and GTEx database. (Fig. 4b). The overall survival of breast cancer patients with high ECSCR expression was longer than that of patients with low ECSCR expression, as determined by Kaplan-Meier analysis (Fig. 4c). RT-qPCR validation of differentially expressed genes and online database analysis of ECSCR. (a) RT-qPCR analysis of some of the differential expression genes from RNA-seq in breast cancer cells treated with DMSO or RES. (b) ECSCR expression in TCGA and GTEx BRCA samples. *P < 0.05. (c) Kaplan-Meier analysis of overall survival for breast cancer patients with high versus low ECSCR. *P < 0.001 ECSCR overexpressing in breast cancer cells inhibits proliferation and migration and promotes apoptosis in vitro To determine the involvement of ECSCR in the inhibitory effect of RES on breast cancer growth, we constructed breast cancer cell lines that stably overexpressed ECSCR (ECSCR-OE) or served as non-overexpressing controls (ECSCR-NC) (Supplementary Fig. 1a and 1b). Proliferation experiments were conducted using ECSCR-NC and ECSCR-OE cells treated with DMSO or RES. MDA-MB-231 ECSCR-OE cells showed a slower proliferation rate compared to MDA-MB-231 ECSCR-NC, but RES treatment did not significantly affect the proliferation rate of MDA-MB-231 ECSCR-OE. Similarly, MCF-7 ECSCR-OE exhibited a slower proliferation rate than MCF-7 ECSCR-NC, and RES treatment further decreased the proliferation rate of MCF-7 ECSCR-OE (Fig. 5a, b). Western blot experiments showed decreased p-ERK expression in MDA-MB-231 cells after ECSCR overexpression, whereas no significant changes were observed in MCF-7 (Fig. 5c). ECSCR overexpressing in breast cancer cells inhibits proliferation, and migration and promotes apoptosis in vitro. (a, b) Proliferation of breast cancer cells with or without ECSCR overexpression and with or without RES treatment was detected by CCK8. (c) Western blot analysis was used to determine the expression levels of ERK protein and p-ERK protein after ECSCR overexpression in MCF-7 and MDA-MB-231 (d, e) The plate cloning assay was used to test the colony-forming ability of breast cancer cells with or without ECSCR overexpression. *P < 0.05. (f, g) Migration ability of breast cancer cells whether overexpressing ECSCR. Scale bar = 400 μm. *P < 0.05 (h) Western blot analysis was used to determine the expression levels of Vimentin protein and SNAIL protein after ECSCR overexpression in MCF-7 and MDA-MB-231 (i, j) Flow cytometry was used to detect apoptosis in breast cancer cells with and without ECSCR overexpression. *P < 0.05. (k) Western blot analysis was used to determine apoptosis-related protein expression after ECSCR overexpression in MCF-7 and MDA-MB-231 In colony formation assays, ECSCR-OE cells showed significantly reduced colony-forming ability compared to ECSCR-NC (Fig. 5d, e). Cell migration assays demonstrated fewer migrating cells in both MDA-MB-231 ECSCR-OE and MCF-7 ECSCR-OE compared to their respective NC groups (Fig. 5f, g). Western blot analysis revealed altered EMT-related protein expression in ECSCR-OE cells: Vimentin and Snail decreased in MDA-MB-231 ECSCR-OE, while MCF-7 ECSCR-OE showed decreased Vimentin but increased Snail (Fig. 5h). Consistent with literature reports on ECSCR’s role in apoptosis, flow cytometry showed higher apoptosis rates in ECSCR-OE cells (Fig. 5i, j). Western blot analysis confirmed reduced anti-apoptotic proteins (Bcl-2 in both cell lines; Bcl-XL specifically in MDA-MB-231) and increased pro-apoptotic proteins (Caspase 3 in both cell lines; Bax specifically in MDA-MB-231) (Fig. 5k and Supplementary Fig. 2). ECSCR overexpression regulates breast cancer cells in vivo To explore the effect of ECSCR on breast cancer cell growth in vivo, we performed subcutaneous xenograft tumor formation experiments in nude mice. The results showed that the tumor volume of MCF-7 and MDA-MB-231 breast cancer cells that did not overexpress ECSCR continued to increase, whereas those overexpressing ECSCR began to decrease two weeks post-implantation (Fig. 6a and b). There was no significant difference in body weight fluctuations between the experimental and control groups (Fig. 6c). ECSCR overexpression regulates breast cancer cells in vivo. (a) Representative xenograft images at 26 days after injection of the indicated breast cancer cells into nude mice. The weight of the xenografts in each group was calculated. (b) Volume changes of xenografts in nude mouse experiments. (c) Weight changes in nude mice in animal experiments. MCF-7, n = 5. MDA-MB-231, n = 6. *P < 0.05 Discussion Numerous bioactive plant-derived compounds exert anticancer effects against breast cancer by modulating key signaling pathways, inducing apoptosis, and inhibiting proliferation [20–23]. In this study, we determined the IC₅₀ of resveratrol (RES) against different breast cancer cell lines. The results indicate that triple-negative breast cancer (TNBC) cells are more sensitive to RES than non-TNBC cells, as evidenced by a lower IC₅₀ value for MDA-MB-231 compared to MCF-7. The mechanism underlying this differential sensitivity has not been fully elucidated in previous reports [18, 19]. To investigate this, we performed RNA sequencing on both cell lines after treatment with their respective IC₅₀ concentrations of RES. Following comparison of differentially expressed genes and subsequent RT-qPCR validation, a significant increase in ECSCR expression was observed in RES-treated MDA-MB-231 cells, whereas no significant change occurred in MCF-7 cells. Analysis of the TCGA database revealed that ECSCR expression is significantly lower in breast cancer tissues than in normal tissues. Consistent with a potential tumor-suppressive role, Kaplan-Meier plotter analysis indicated that breast cancer patients with low ECSCR expression had shorter overall survival than those with high expression. Given these findings and the limited reports on ECSCR function in tumors, we hypothesized that ECSCR acts as a tumor suppressor in breast cancer and may contribute to the observed difference in RES sensitivity. To test this, we performed functional validation by constructing lentivirus-mediated ECSCR-overexpressing (ECSCR-OE) and corresponding control cell lines. Proliferation assays demonstrated that ECSCR overexpression led to a slower proliferation rate compared to controls. Notably, the proliferation rate of MCF-7 ECSCR-OE cells was further reduced by RES treatment, whereas no significant difference was observed between RES-treated and untreated MDA-MB-231 ECSCR-OE groups. Western blot analysis showed decreased phosphorylated ERK (p-ERK) expression in MDA-MB-231 cells upon ECSCR overexpression, but no significant change in MCF-7 cells. Given that the RAF-MEK-ERK pathway regulates critical cellular processes including proliferation, differentiation, and apoptosis [24], these results suggest that ECSCR overexpression inhibits breast cancer cell proliferation, potentially via suppression of the RAF-MEK-ERK pathway in TNBC. In colony formation assays, both MDA-MB-231 and MCF-7 ECSCR-OE cells formed fewer colonies than their respective control groups. Transwell migration assays further revealed that ECSCR overexpression reduced migratory capacity. Western blot analysis of epithelial-to-mesenchymal transition (EMT)-related proteins showed decreased Vimentin expression in ECSCR-OE cells compared to controls. Snail expression was reduced in MDA-MB-231 ECSCR-OE cells but increased in MCF-7 ECSCR-OE cells, suggesting cell line-specific responses [25–29]. These findings imply that ECSCR overexpression downregulates Vimentin, thereby reducing migration. In TNBC, RES may suppress Snail expression via ECSCR upregulation, attenuating EMT and decreasing Vimentin to inhibit migration. Flow cytometry analysis indicated increased apoptosis in ECSCR-OE cells. Correspondingly, Western blot showed that ECSCR overexpression decreased anti-apoptotic proteins BCL-2 and Bcl-XL while increasing cleaved Caspase-3. As RES is known to induce apoptosis in cancer cells [30], our data suggest that RES may promote apoptosis, at least in part, through ECSCR upregulation. In vivo, tumor volume was significantly smaller in the ECSCR-OE group compared to the control group, indicating reduced tumorigenicity in nude mice. In conclusion, this study demonstrates that ECSCR inhibits proliferation, colony formation, and migration of breast cancer cells while promoting apoptosis. ECSCR overexpression also suppresses tumor growth in vivo. The differential sensitivity of TNBC and non-TNBC cells to RES may stem from differential ECSCR induction following RES treatment. These findings position ECSCR as a potential therapeutic target for breast cancer, particularly TNBC. Study limitations include the absence of ECSCR knockdown experiments, the use of a limited number of cell lines, and an incomplete elucidation of the upstream regulators and downstream effectors through which ECSCR exerts its effects. The precise molecular mechanisms of the RES-ECSCR interaction also require further investigation. Additional clinical studies and mechanistic explorations are warranted. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1—Establishment of ECSCR-overexpressing breast cancer cell lines. (a) RT-qPCR analysis of ECSCR mRNA expression in MCF-7 and MDA-MB-231 after lentivirus transfection. *P < 0.05. (b) Western blot analysis of ECSCR protein expression in MCF-7 and MDA-MB-231 after lentivirus transfection Supplementary Material 2—Western blot analysis was used to detect the expression of cleaved-PARP and Bax in the MCF-7 and MDA-MB-231 cell lines after ECSCR overexpression Supplementary Material 3—Uncropped Western blot membrane of ECSCR overexpression in breast cancer cell lines. Supplementary Material 4—The uncropped Western blot membranes of proliferation-related proteins in breast cancer cell lines with or without ECSCR overexpression. Supplementary Material 5—The uncropped Western blot membranes of migration-related proteins in breast cancer cell lines with or without ECSCR overexpression. Supplementary Material 6—The uncropped Western blot membranes of apoptosis-related proteins in breast cancer cell lines with or without ECSCR overexpression. Supplementary Material 7—The uncropped Western blot membranes of cleaved-PARP and Bax in breast cancer cell lines with or without ECSCR overexpression. Acknowledgements Not applicable. Author contributions Sen Lian, Yi Huang: data curation, formal analysis, methodology, validation, visualization, writing – original draft, writing – review and editing. Ling Liang, Yiping Yang, Yingxi Mo: data curation, validation. Shan Wang, Changyuan Wei: conceptualization, project administration, supervision, writing – review and editing. All authors prepared the manuscript and approved the final manuscript. Funding Middle/Young aged Teachers' Research Ability Improvement Project of Guangxi Higher Education(2024KY0092). Guangxi Health Commission self-funded scientific research project (Z-A20220736). Guangxi Natural Science Foundation (2020GXNSFAA297152). Data availability The datasets generated and analyzed during the current study are available in the National Center for Biotechnology Information, https://www.ncbi.nlm.nih.gov/sra/PRJNA1163537 Declarations Competing interests The authors have no conflict of interest. Ethics approval Animal studies were reviewed and approved by Guangxi Medical UniversityAnimal studies were reviewed and approved by Guangxi Medical University. Patient consent Not applicable. Clinical trial registration Not applicable. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Sen Lian and Yi Huang have contributed equal to this work. Contributor Information Shan Wang, Email: wangshan@sr.gxmu.edu.cn. Changyuan Wei, Email: changyuanwei@gxmu.edu.cn. References Associated Data Supplementary Materials Supplementary Material 1—Establishment of ECSCR-overexpressing breast cancer cell lines. (a) RT-qPCR analysis of ECSCR mRNA expression in MCF-7 and MDA-MB-231 after lentivirus transfection. *P < 0.05. (b) Western blot analysis of ECSCR protein expression in MCF-7 and MDA-MB-231 after lentivirus transfection Supplementary Material 2—Western blot analysis was used to detect the expression of cleaved-PARP and Bax in the MCF-7 and MDA-MB-231 cell lines after ECSCR overexpression Supplementary Material 3—Uncropped Western blot membrane of ECSCR overexpression in breast cancer cell lines. Supplementary Material 4—The uncropped Western blot membranes of proliferation-related proteins in breast cancer cell lines with or without ECSCR overexpression. Supplementary Material 5—The uncropped Western blot membranes of migration-related proteins in breast cancer cell lines with or without ECSCR overexpression. Supplementary Material 6—The uncropped Western blot membranes of apoptosis-related proteins in breast cancer cell lines with or without ECSCR overexpression. Supplementary Material 7—The uncropped Western blot membranes of cleaved-PARP and Bax in breast cancer cell lines with or without ECSCR overexpression. Data Availability Statement The datasets generated and analyzed during the current study are available in the National Center for Biotechnology Information, https://www.ncbi.nlm.nih.gov/sra/PRJNA1163537